Adrenal hyperplasia in adults is not a single condition but a family of disorders in which one or both adrenal glands grow larger than normal, producing excess hormones that quietly disrupt blood pressure, metabolism, fertility, or all three. The most common form seen in adult clinics is non-classic congenital adrenal hyperplasia, a genetic enzyme deficiency that often goes unrecognized until someone investigates stubborn acne, irregular periods, or unexplained hair growth. Other forms include bilateral adrenal hyperplasia driving primary aldosteronism and macronodular hyperplasia causing cortisol excess. Each type has distinct signs, its own diagnostic pathway, and different treatment trade-offs worth understanding.
Non-Classic Congenital Adrenal Hyperplasia
Non-classic congenital adrenal hyperplasia (NCCAH) is the form most frequently diagnosed in adult life. It stems from partial deficiency of the 21-hydroxylase enzyme, encoded by the CYP21A2 gene on chromosome 6.1PubMed Central. Nonclassic congenital adrenal hyperplasia Unlike the classic form, which causes life-threatening salt-wasting crises in infancy, NCCAH leaves enough enzyme activity intact to keep cortisol roughly adequate. The trouble is that the adrenal glands compensate by overproducing androgens, the hormones responsible for body hair, oily skin, and certain aspects of reproductive function.
Most people with NCCAH are diagnosed during adolescence or adulthood. Women typically present with hirsutism, persistent acne, menstrual irregularity, or a clinical picture that looks a lot like polycystic ovary syndrome. Fertility issues also bring women to diagnosis. Men with NCCAH, by contrast, frequently escape detection altogether because mild androgen excess does not produce obvious symptoms in males.2European journal of endocrinology. Diagnosis and management of the patient with non-classic CAH due to 21-hydroxylase deficiency
Prevalence varies by ancestry. Revised estimates put NCCAH at about 1 in 200 among white populations, and carrier rates run around 10 to 15 percent in both Ashkenazi Jewish and broader Caucasian groups.3PubMed Central. Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians Specific CYP21A2 mutations cluster in certain ethnic groups. The mild V281L mutation, for instance, is the most common among Ashkenazi Jews, while large gene deletions dominate in Native American and Anglo-Saxon populations.4Human Reproduction Update. Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women
Why NCCAH Gets Confused with PCOS
One of the biggest practical problems with NCCAH is that it mimics polycystic ovary syndrome so convincingly that many women are never tested for it. Both conditions produce hirsutism, irregular cycles, and elevated androgens. A study evaluating women referred for hirsutism, infertility, or atypical PCOS found that roughly 13 percent of that cohort actually had genetically verified NCCAH.5Fertility and Sterility. Adrenal steroid profiling as a diagnostic tool to differentiate PCOS from non-classical congenital adrenal hyperplasia That is not a trivial number. If you have been told you have PCOS but your symptoms do not respond well to standard treatment, or if you have a family history of adrenal problems, asking about NCCAH screening is reasonable.
The distinguishing blood test is a morning measurement of 17-hydroxyprogesterone (17-OHP), the steroid that accumulates upstream of the enzyme block. A baseline level at or above about 6 nmol/L accurately screens for NCCAH with roughly 96 percent sensitivity and specificity.6Journal of the Endocrine Society. Screening for Nonclassic Congenital Adrenal Hyperplasia in the Era of Liquid Chromatography-Tandem Mass Spectrometry When results are borderline, a cosyntropin stimulation test can clarify things. In one retrospective study, a baseline 17-OHP cut-off near 2.8 ng/mL offered a good balance of sensitivity and specificity for deciding who needs that stimulation test.7PubMed Central. What Cut-off Value of 17-Hydroxyprogesterone Should Be an Indication to Perform a 250 µg Cosyntropin Stimulation Test When NCCAH Is Suspected? Genetic testing of CYP21A2 confirms the diagnosis when needed.8PubMed Central. Identifying the First Val281L Mutation Causing Nonclassic Congenital Adrenal Hyperplasia in the Central-East Region of Tunisia
Treating NCCAH in Adults
Not every adult with NCCAH needs treatment. If the condition is discovered incidentally and you do not have bothersome symptoms, watchful observation is a legitimate choice. When treatment is warranted, the goals are typically to control androgen-driven symptoms and, for women trying to conceive, to restore normal ovulation.
Low-dose glucocorticoids such as hydrocortisone can dial down the adrenal androgen overproduction by reducing the signal that drives it. However, glucocorticoid therapy is a double-edged sword. Supraphysiological doses risk bone loss, weight gain, insulin resistance, and even hypertension over time.9PubMed. Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome Long-term glucocorticoid use also produces iatrogenic adrenal insufficiency, meaning the remaining healthy adrenal tissue gets suppressed and cannot mount a normal stress response. For this reason, current expert guidance favors keeping glucocorticoid courses short and at the lowest effective dose, and in many cases preferring alternatives altogether.10PubMed Central. Management of the Female With Non-classical Congenital Adrenal Hyperplasia (NCCAH): A Patient-Oriented Approach
Those alternatives include antiandrogens like spironolactone or cyproterone acetate, which block androgen action at the tissue level without suppressing the adrenal glands, and combined oral contraceptives, which both suppress ovarian androgens and regulate cycles. A recent review noted that these options are preferable in many cases because they avoid the metabolic complications of glucocorticoids.11PubMed. Non-classical congenital adrenal hyperplasia: current insights into clinical implications, diagnosis and treatment For women specifically trying to conceive, short-term glucocorticoid use may still be needed to normalize progesterone levels that could otherwise interfere with implantation, though reported pregnancy rates in NCCAH women are generally normal even without treatment.12Frontiers in Endocrinology. Challenges in treatment of patients with non-classic congenital adrenal hyperplasia
Primary Aldosteronism and Bilateral Adrenal Hyperplasia
A completely different form of adrenal hyperplasia shows up in the blood-pressure clinic. Primary aldosteronism is the most common cause of secondary hypertension, and in roughly two-thirds of cases it is driven by bilateral adrenal hyperplasia rather than a single hormone-secreting tumor.13PubMed. Treatment of primary aldosteronism Excess aldosterone causes the body to retain sodium and water while dumping potassium, leading to resistant high blood pressure and sometimes muscle cramps, weakness, or heart rhythm disturbances.
Compared with ordinary high blood pressure, primary aldosteronism causes disproportionate damage to the heart, kidneys, and blood vessels, with higher rates of heart failure, stroke, heart attack, and atrial fibrillation.14Circulation. Primary Aldosteronism: Practical Approach to Diagnosis and Management This is why identifying it matters: treating the aldosterone excess specifically, rather than just adding more blood-pressure pills, changes long-term outcomes.
Screening starts with an aldosterone-to-renin ratio in a blood draw. A positive screen should generally be followed by a confirmatory test, such as a saline infusion test or captopril challenge, to rule out false positives before moving to invasive procedures. An exception is made for patients who already have striking features like spontaneous low potassium alongside very high aldosterone and undetectable renin, where the diagnosis is essentially certain.15PubMed. The role of confirmatory tests in the diagnosis of primary aldosteronism
The critical next step is figuring out whether one gland or both is the source. CT imaging can show nodules, but it is not reliable enough on its own to tell a functioning adenoma from bilateral hyperplasia. Adrenal vein sampling, where blood is drawn directly from each adrenal vein to compare aldosterone levels, remains the gold standard for making that distinction.16PubMed. Adrenal vein sampling When one gland is clearly the culprit, surgical removal can be curative. When both glands are hyperplastic, the treatment shifts to medication: mineralocorticoid receptor antagonists like spironolactone, typically started at a low dose and titrated upward, with eplerenone as an alternative that tends to cause fewer side effects like breast tenderness.13PubMed. Treatment of primary aldosteronism 17European Journal of Endocrinology. Medical treatment of primary aldosteronism
Macronodular Hyperplasia and Cortisol Excess
Primary macronodular adrenal hyperplasia (PMAH, also called PBMAH) is a rarer condition in which both adrenal glands develop large nodules that autonomously produce cortisol, independent of the normal pituitary signal. It accounts for a small share of adrenal Cushing syndrome cases. The clinical picture is highly variable: some patients develop full-blown Cushing syndrome with weight gain concentrated in the face and trunk, thin skin, easy bruising, high blood sugar, and muscle weakness, while others have only subtle cortisol excess detectable on lab testing.18PubMed Central. An Overview of the Heterogeneous Causes of Cushing Syndrome Resulting From Primary Macronodular Adrenal Hyperplasia (PMAH)
What makes PMAH biologically interesting is that the excess steroid production is often driven by receptors that should not be active in adrenal tissue. Various abnormally expressed receptors respond to signals like food intake, hormones from the gut, or other circulating molecules, creating an unusual form of hormone regulation within the adrenal nodules themselves.19Endocrine Reviews. Clinical, Pathophysiologic, Genetic, and Therapeutic Progress in Primary Bilateral Macronodular Adrenal Hyperplasia One striking example involves genetic inactivation of the KDM1A gene, which leads to abnormal expression of a receptor for gastric inhibitory peptide in adrenal cells, producing a form of Cushing syndrome where cortisol levels spike after meals.20Nature Reviews Endocrinology. Primary bilateral macronodular adrenal hyperplasia: definitely a genetic disease
Surgical guidelines suggest that when PMAH is causing clinically significant cortisol excess, unilateral removal of the larger or more active gland can reduce hormone levels enough to achieve remission without leaving the patient permanently dependent on steroid replacement pills.21JAMA Surgery. American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive Summary – Section: Hypercortisolism In younger patients or those with metabolic complications that are hard to control medically, surgery tends to be favored more readily.22Journal of the Endocrine Society. A New Insight into the Surgical Treatment of Primary Macronodular Adrenal Hyperplasia
A Related Genetic Syndrome in Younger Adults
Primary pigmented nodular adrenocortical disease (PPNAD) is a distinct condition worth mentioning because it can cause Cushing syndrome in teenagers and young adults. Rather than the large nodules of PMAH, PPNAD features small, darkly pigmented nodules studding both adrenal glands. It is most commonly part of Carney complex, an inherited syndrome that also involves cardiac tumors, spotty skin pigmentation, and other endocrine abnormalities. Mutations in the PRKAR1A gene account for the majority of cases; germline mutations in this gene have been found in up to 80 percent of Carney complex patients who develop Cushing syndrome from PPNAD.23PubMed. PRKAR1A mutations in primary pigmented nodular adrenocortical disease Because the disease is bilateral, treatment typically involves removing both adrenal glands, which commits the patient to lifelong glucocorticoid and mineralocorticoid replacement.
Adrenal Incidentalomas That Reveal Hyperplasia
Many adults learn they have adrenal enlargement or nodules not because of symptoms but because a CT scan done for an unrelated reason catches an adrenal mass. These incidentalomas are common. While the majority are benign and non-functioning, a meaningful minority turn out to be hormonally active or warrant further investigation based on size and imaging features.24PubMed Central. The Landmark Series: Evaluation and Management of Adrenal Incidentalomas
The standard workup involves biochemical testing for cortisol excess, aldosterone overproduction, and catecholamine excess (to rule out a pheochromocytoma). For cortisol, the European Society of Endocrinology guidelines recommend a 1-milligram overnight dexamethasone suppression test. If cortisol does not suppress below a specific threshold the next morning, the finding is classified as mild autonomous cortisol secretion, and clinicians then assess whether the patient has related metabolic problems such as diabetes, hypertension, or osteoporosis that could be driven by even subtle cortisol excess.25European Journal of Endocrinology. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas
Non-functioning nodules under 4 cm typically get imaging surveillance rather than surgery. Functional tumors and those 4 cm or larger, or growing rapidly, generally warrant surgical removal.24PubMed Central. The Landmark Series: Evaluation and Management of Adrenal Incidentalomas The reassuring reality is that most patients with an incidental adrenal finding can be evaluated, managed with a personalized plan, and many will not need surgery at all.26Endocrine Reviews. Adrenal Incidentaloma
Recovery After Adrenal Surgery
One concern that does not get discussed enough is what happens to the remaining adrenal gland after surgery. When one gland has been autonomously pumping out cortisol for months or years, the other gland’s normal cortisol-producing tissue gets suppressed. After the overactive gland is removed, it can take the remaining gland weeks to months to wake back up.
In a study of patients who had one adrenal gland removed for mild autonomous cortisol secretion, about 70 percent recovered adrenal function within roughly 15 months. The median duration of post-surgical adrenal insufficiency was around 4 months, and recovery was fastest in patients who had milder cortisol excess before surgery: about 3 months for mild cases versus over 14 months for severe ones.27The Journal of Clinical Endocrinology & Metabolism. Cortisol Testing to Diagnose Adrenal Insufficiency Following Adrenalectomy for Mild Autonomous Cortisol Secretion During the recovery window, patients need stress-dose glucocorticoid coverage for illness, injury, or surgery, and regular testing to determine when replacement can safely stop.
Even patients who undergo adrenalectomy for non-cortisol-producing tumors sometimes show low cortisol levels right after surgery. In one study, about 37 percent of these patients had measurably low cortisol postoperatively, though most did not develop clinical symptoms of adrenal insufficiency.28PubMed. Biochemical assessment of adrenal insufficiency after adrenalectomy for non-cortisol secreting tumors: clinical correlation and recommendations The takeaway is that postoperative cortisol monitoring matters regardless of the original tumor type, and management approaches vary from automatic steroid coverage to testing-based decisions about who really needs replacement.
Living with Adrenal Hyperplasia as an Adult
The day-to-day burden of adrenal hyperplasia goes beyond hormone levels. Adults with congenital adrenal hyperplasia report diminished quality of life across several domains, with lower scores particularly in areas related to adrenal insufficiency symptoms, mental health, and sexual function. Physical and sexual functioning scores tend to decline with age, and women score lower than men in areas related to glucocorticoid side effects and sexual well-being.29Frontiers in Endocrinology. Living with congenital adrenal hyperplasia: insights on quality of life
That said, the picture is not uniformly grim. One comparison study found that while CAH patients had impaired well-being on some measures, their general health perception and mental health scores on broader questionnaires did not differ significantly from healthy controls.30PubMed. Quality of life is less impaired in adults with congenital adrenal hyperplasia because of 21-hydroxylase deficiency than in patients with primary adrenal insufficiency Among men with CAH, quality of life was similar to controls overall, though men diagnosed later in life showed more depressive symptoms and lower self-control scores. Sexual satisfaction was comparable, but a higher proportion of CAH men reported being sexually inactive.31PubMed. Quality of life, social situation, and sexual satisfaction, in adult males with congenital adrenal hyperplasia
These findings underscore that managing adrenal hyperplasia in adulthood is as much about managing the treatment as managing the disease. Glucocorticoid replacement that is slightly too high erodes bone density and metabolic health over years; doses that are too low leave androgen excess uncontrolled and risk adrenal crises during illness. Finding the right balance requires ongoing collaboration with an endocrinologist, periodic lab work, and honest conversations about which symptoms are most affecting your daily life. The social dimension, including occupational choices, relationships, and mental health, deserves attention alongside the hormone numbers on a lab printout.
What Drives Adrenal Tissue to Grow
The biological process behind adrenal hyperplasia varies by condition, but a shared thread is chronic stimulation. In NCCAH, the adrenal cortex enlarges because insufficient cortisol production triggers a persistent feedback loop, driving the glands to work harder. In primary aldosteronism, somatic mutations in ion channels within adrenal cells appear to initiate the process, and the fact that such mutations arise frequently may explain why the condition is so common.14Circulation. Primary Aldosteronism: Practical Approach to Diagnosis and Management
Prolonged stimulation by ACTH, the pituitary hormone that drives cortisol production, leads to increased protein and RNA synthesis in adrenal cells. The resulting cell proliferation physically enlarges the glands, and gland weight can increase substantially.32PubMed Central. Effects of Chronic ACTH Excess on Human Adrenal Cortex Whether a hyperplastic nodule stays benign or acquires autonomous behavior appears to depend on the interplay between cell proliferation and programmed cell death. Research on adrenal nodules has shown that a dominant clone expands when proliferation is high and cell death is simultaneously suppressed, a combination that gives certain cell populations a growth advantage.33PubMed Central. Clonality as expression of distinctive cell kinetics patterns in nodular hyperplasias and adenomas of the adrenal cortex This helps explain why hyperplastic glands sometimes develop nodules that eventually behave like adenomas, blurring the clinical line between the two.